uniQure N.V. (QURE)
QURE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/0001104659-26-021898-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | QURE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | 2014 |
| SEC CIK | 0001590560 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $16.1M |
| Net income | -$199.0M |
| Operating income | -$185.3M |
| Net margin | -1236.2% |
| Operating margin | -1151.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $80.2M |
| Total assets | $824.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 91.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-24 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-07-29 |
| Latest current report FORM 8-K | 8-K | 2026-09-29 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 948 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.8% |
| 1 month | -52.1% |
| 3 months | -47.5% |
| Year to date | -13.7% |
| 1 year | -66.7% |
| From 52-week high | -70.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | $14.92 | -2.48% | $1.5B |
| PAHC | Phibro Animal Health Corporation | $36.81 | -1.66% | $1.5B |
| INVA | Innoviva Inc. | $20.74 | -3.31% | $1.5B |
| STOK | Stoke Therapeutics Inc. | $22.50 | -6.83% | $1.5B |
| PCRX | Pacira BioSciences Inc. | $36.31 | -0.11% | $1.4B |
| KRSA | Korsana Biosciences Inc. | $31.66 | -6.99% | $1.4B |
| ETON | Eton Pharmaceuticals Inc. | $53.33 | -3.48% | $1.5B |
| CMPS | COMPASS Pathways Plc American Depository Shares | $11.14 | -3.38% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier